These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26119500)

  • 1. Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors.
    Yang Z; Ma H; Sun Z; Luo L; Tian S; Zheng J; Zhang X
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3665-70. PubMed ID: 26119500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
    Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y
    Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
    Graab U; Hahn H; Fulda S
    Oncotarget; 2015 Apr; 6(11):8722-35. PubMed ID: 25749378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzo[b]furan derivatives induces apoptosis by targeting the PI3K/Akt/mTOR signaling pathway in human breast cancer cells.
    Kamal A; Lakshma Nayak V; Nagesh N; Vishnuvardhan MV; Subba Reddy NV
    Bioorg Chem; 2016 Jun; 66():124-31. PubMed ID: 27149364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
    Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
    Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
    Cheng H; Hoffman JE; Le PT; Pairish M; Kania R; Farrell W; Bagrodia S; Yuan J; Sun S; Zhang E; Xiang C; Dalvie D; Rahavendran SV
    Bioorg Med Chem Lett; 2013 May; 23(9):2787-92. PubMed ID: 23506825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of anilide (dicarboxylic acid) shikonin esters as antitumor agents through targeting PI3K/Akt/mTOR signaling pathway.
    Ma Y; Yang X; Han H; Wen Z; Yang M; Zhang Y; Fu J; Wang X; Yin T; Lu G; Qi J; Lin H; Wang X; Yang Y
    Bioorg Chem; 2021 Jun; 111():104872. PubMed ID: 33838560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel anti-prostate cancer scaffold identified by the combination of in silico and cell-based assays targeting the PI3K-AKT-mTOR pathway.
    Saidel MÉ; Dos Santos KC; Nagano LFP; Montanari CA; Leitão A
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4001-4006. PubMed ID: 28774426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
    Slomovitz BM; Coleman RL
    Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
    Brechbiel J; Miller-Moslin K; Adjei AA
    Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors.
    Saurat T; Buron F; Rodrigues N; de Tauzia ML; Colliandre L; Bourg S; Bonnet P; Guillaumet G; Akssira M; Corlu A; Guillouzo C; Berthier P; Rio P; Jourdan ML; Bénédetti H; Routier S
    J Med Chem; 2014 Feb; 57(3):613-31. PubMed ID: 24345273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
    Wolin EM
    Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hedgehog inhibitor sonidegib potentiates
    Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
    BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
    Abraham J
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):51-68. PubMed ID: 25306975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates.
    Mazzoletti M; Bortolin F; Brunelli L; Pastorelli R; Di Giandomenico S; Erba E; Ubezio P; Broggini M
    Cancer Res; 2011 Jul; 71(13):4573-84. PubMed ID: 21602434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
    Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
    J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel pyrazolochalcones as potential modulators of PI3K/Akt/mTOR pathway and inducers of apoptosis in breast cancer cells.
    Shaik AB; Rao GK; Kumar GB; Patel N; Reddy VS; Khan I; Routhu SR; Kumar CG; Veena I; Chandra Shekar K; Barkume M; Jadhav S; Juvekar A; Kode J; Pal-Bhadra M; Kamal A
    Eur J Med Chem; 2017 Oct; 139():305-324. PubMed ID: 28803046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
    Blachly JS; Baiocchi RA
    Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.